MA44309A - Oligonucléotides antisens il-34 et leurs procédés d'utilisation - Google Patents

Oligonucléotides antisens il-34 et leurs procédés d'utilisation

Info

Publication number
MA44309A
MA44309A MA044309A MA44309A MA44309A MA 44309 A MA44309 A MA 44309A MA 044309 A MA044309 A MA 044309A MA 44309 A MA44309 A MA 44309A MA 44309 A MA44309 A MA 44309A
Authority
MA
Morocco
Prior art keywords
fibrosis
inflammatory diseases
antisens
oligonucleotides
use methods
Prior art date
Application number
MA044309A
Other languages
English (en)
Inventor
Salvatore Bellinvia
Marie Mcnulty
Francesca Viti
Original Assignee
Nogra Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Publication date
Publication of MA44309A publication Critical patent/MA44309A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1136—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against growth factors, growth regulators, cytokines, lymphokines or hormones
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/32—Special delivery means, e.g. tissue-specific

Abstract

La présente invention concerne des séquences oligonucléotidiques antisens dirigées contre l'il-34 et des procédés de traitement de maladies inflammatoires, telles que la maladie inflammatoire de l'intestin et / ou la fibrose, associées à une activité ou une expression élevée de l'il-34. L'invention concerne également des compositions pharmaceutiques contenant un oligonucléotide antisens il-34 utile pour traiter les maladies inflammatoires et / ou la fibrose et la fabrication de médicaments contenant un oligonucléotide antisens il-34 décrit à utiliser dans le traitement des maladies inflammatoires et / ou de la fibrose.
MA044309A 2015-11-25 Oligonucléotides antisens il-34 et leurs procédés d'utilisation MA44309A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562260076P 2015-11-25 2015-11-25

Publications (1)

Publication Number Publication Date
MA44309A true MA44309A (fr) 2018-10-03

Family

ID=57471829

Family Applications (1)

Application Number Title Priority Date Filing Date
MA044309A MA44309A (fr) 2015-11-25 Oligonucléotides antisens il-34 et leurs procédés d'utilisation

Country Status (13)

Country Link
US (1) US20180338992A1 (fr)
EP (1) EP3380615B1 (fr)
JP (2) JP2018535681A (fr)
KR (1) KR20180084956A (fr)
CN (1) CN108473989A (fr)
AU (1) AU2016360956A1 (fr)
BR (1) BR112018010736A2 (fr)
CA (1) CA3005932A1 (fr)
ES (1) ES2861516T3 (fr)
MA (1) MA44309A (fr)
MX (1) MX2018006445A (fr)
PT (1) PT3380615T (fr)
WO (1) WO2017089555A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3420082A4 (fr) * 2016-02-23 2019-10-16 Celgene Alpine Investment Company II, LLC Méthodes de traitement de la fibrose intestinale par inhibition de smad7
BR112022009254A2 (pt) * 2019-11-15 2022-10-04 Nogra Pharma Ltd Agentes antissenso il-34 e métodos de usar os mesmos
WO2022243299A1 (fr) * 2021-05-17 2022-11-24 Nogra Pharma Limited Agents anti-sens il-34 et leurs procédés d'utilisation

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7250496B2 (en) * 2002-11-14 2007-07-31 Rosetta Genomics Ltd. Bioinformatically detectable group of novel regulatory genes and uses thereof
EP2242854A4 (fr) * 2008-01-15 2012-08-15 Quark Pharmaceuticals Inc Composés d'arnsi et leurs utilisations
EP2364360B1 (fr) 2008-11-13 2017-03-22 Nogra Pharma Limited Compositions antisens et procédés de préparation et d'utilisation de celles-ci
GB0910833D0 (en) * 2009-06-23 2009-08-05 Univ Edinburgh Avian genes
WO2011097407A1 (fr) * 2010-02-04 2011-08-11 Ico Therapeutics Inc. Schémas posologiques permettant de traiter et de prévenir des affections oculaires au moyen d'oligonucléotides c-raf antisens
AR080698A1 (es) * 2010-04-01 2012-05-02 Imclone Llc Anticuerpo o fragmento del mismo que especificamente enlaza la variante de csf -1r humano, composicion farmaceutica que lo comprende, su uso para la manufactura de un medicamento util para el tratamiento de cancer y metodo para determinar si un sujeto es candidato para tratamiento de cancer basado e
CA2841013C (fr) * 2011-07-18 2020-04-21 Morphosys Ag Utilisation d'antagonistes de c-fms
AU2013308635A1 (en) * 2012-08-31 2015-03-12 Five Prime Therapeutics, Inc. Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (CSF1R)
GB201315486D0 (en) * 2013-08-30 2013-10-16 Ucb Pharma Sa Antibodies
KR20150104275A (ko) * 2014-03-05 2015-09-15 울산대학교 산학협력단 비만 관련 질환의 진단과 치료를 위한 il-34의 용도
WO2016011080A2 (fr) * 2014-07-14 2016-01-21 The Regents Of The University Of California Modulation transcriptionnelle par crispr/cas

Also Published As

Publication number Publication date
JP2018535681A (ja) 2018-12-06
ES2861516T3 (es) 2021-10-06
JP2021106625A (ja) 2021-07-29
US20180338992A1 (en) 2018-11-29
PT3380615T (pt) 2021-04-01
EP3380615A1 (fr) 2018-10-03
AU2016360956A1 (en) 2018-06-07
KR20180084956A (ko) 2018-07-25
CN108473989A (zh) 2018-08-31
BR112018010736A2 (pt) 2018-11-27
CA3005932A1 (fr) 2017-06-01
EP3380615B1 (fr) 2021-01-06
MX2018006445A (es) 2018-08-01
WO2017089555A1 (fr) 2017-06-01

Similar Documents

Publication Publication Date Title
WO2015106128A3 (fr) Agents d'arni modifiés
BRPI0412909A (pt) uso de rnai inibindo atividade de parp para a fabricação de um medicamento para o tratamento de cáncer
PH12020500309A1 (en) Rnai agents and compositions for inhibiting expression of angiopoietin-like 3 (angptl3), and methods of use
MX2020011570A (es) Administracion extrahepatica.
Kim et al. Epigenetic modulation as a therapeutic approach for pulmonary arterial hypertension
MA43347B1 (fr) Compositions et méthodes permettant d'inhiber l'expression du gène de lpa
SG10201903290YA (en) Modified double-stranded rna agents
WO2014022739A3 (fr) Agents constitués d'arni modifié
MX359548B (es) Agentes de iarn modificados.
MX2023008478A (es) Nucleótidos modificados con 5´-ciclo-fosfonato.
WO2017019660A8 (fr) Compositions d'arni de xanthine déshydrogénase et leurs méthodes d'utilisation
EA201591932A1 (ru) ПРИМЕНЕНИЕ ЗАМЕЩЕННЫХ 2,3-ДИГИДРОИМИДАЗО[1,2-c]ХИНАЗОЛИНОВ ДЛЯ ЛЕЧЕНИЯ ЛИМФОМ
PH12021550931A1 (en) New anthelmintic compounds
RU2014101547A (ru) Апоптоз-индуцирующее средство
MX2010003299A (es) Oligonucleotidos muy cortos (micromirs).
BR112021024463A2 (pt) Oligonucleotídeos e métodos de uso para o tratamento de doenças neurológicas
EA201792103A1 (ru) Композиции и способы для ингибирования экспрессии генов hif2альфа
FR2920978B1 (fr) Composition cosmetique comprenant un copolymere cationique et un amidon et procede de traitement cosmetique.
MA38190A2 (fr) Inhibiteurs d'autotaxine
Tehrani et al. Competing endogenous RNAs (CeRNAs): novel network in neurological disorders
WO2008045576A3 (fr) Compositions et procédés dans lesquels sont utilisés des agents thérapeutiques à base d'arni, destinés au traitement du cancer et d'autres maladies liées à la néovascularisation
EA202091693A1 (ru) Антисмысловые олигонуклеотиды, целенаправленно воздействующие на альфа-синуклеин, и их применения
MX2013010524A (es) Combinacion de oligonucleotido anti-clusterina con inhibidor hsp90 para el tratamiento de cancer de prostata.
BR112018010736A2 (pt) oligonucleotídeos antissenso contra il-34 e métodos de uso dos mesmos
BR112017001971A2 (pt) ?métodos e composições para diagnosticar e tratar distúrbios inflamatórios intestinais?